0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Letters |

Colorectal Cancer in Women After Stopping Postmenopausal Hormone Therapy—Reply

Rowan T. Chlebowski, MD, PhD
JAMA. 2008;299(23):2744-2745. doi:10.1001/jama.299.23.2744-b.
Text Size: A A A
Published online

Extract

In Reply: Dr Odell suggests that an increase in colorectal cancer incidence in women should be expected now that use of postmenopausal hormone therapy has declined. Although we do not share his opinion that this is the most important implication of the postintervention report from the WHI, we agree that vigilance in this area is warranted.

We reported in the WHI randomized trial that 44% fewer invasive colorectal cancers were diagnosed in participants in the conjugated equine estrogen plus medroxyprogesterone acetate group compared with those in the placebo group.1 However, we also noted that the colorectal cancers were found at higher stage, and a role for delayed assessment of clinical symptoms could not be excluded as a factor influencing this finding.1 In contrast, the incidence of invasive breast cancer was significantly increased by combined hormone therapy in the same trial2; in the present study, although more breast cancers continue to be seen in the hormone group, after the intervention ended a downward inflection in the temporal trend in cumulative hazard ratios for breast cancer was observed.

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

June 18, 2008
Timothy W. Odell, MD
JAMA. 2008;299(23):2744-2745. doi:10.1001/jama.299.23.2744-a.
CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();